NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $69.40 +2.23 (+3.32 %) (As of 01/20/2020 07:10 AM ET) Add Compare Today's Range$66.90Now: $69.40▼$69.8850-Day Range$47.29MA: $60.52▼$69.9352-Week Range$19.88Now: $69.40▼$70.00Volume433,128 shsAverage Volume486,155 shsMarket Capitalization$3.54 billionP/E RatioN/ADividend YieldN/ABeta2.03 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCPH Previous Symbol CUSIPN/A CIK1654151 Webhttp://www.deciphera.com/ Phone781-209-6400Debt Debt-to-Equity RatioN/A Current Ratio15.20 Quick Ratio15.20Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$7.43 per share Price / Book9.34Profitability EPS (Most Recent Fiscal Year)($2.82) Net Income$-99,850,000.00 Net MarginsN/A Return on Equity-46.67% Return on Assets-42.10%Miscellaneous Employees112 Outstanding Shares51,040,000Market Cap$3.54 billion Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive DCPH News and Ratings via Email Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DCPH Rates by TradingView Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions What is Deciphera Pharmaceuticals' stock symbol? Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH." How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its quarterly earnings results on Monday, November, 4th. The company reported ($1.28) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.19) by $0.09. View Deciphera Pharmaceuticals' Earnings History. When is Deciphera Pharmaceuticals' next earnings date? Deciphera Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Deciphera Pharmaceuticals. What price target have analysts set for DCPH? 11 Wall Street analysts have issued 1-year price objectives for Deciphera Pharmaceuticals' stock. Their forecasts range from $29.00 to $77.00. On average, they anticipate Deciphera Pharmaceuticals' share price to reach $59.09 in the next year. This suggests that the stock has a possible downside of 14.9%. View Analyst Price Targets for Deciphera Pharmaceuticals. What is the consensus analysts' recommendation for Deciphera Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Deciphera Pharmaceuticals. Has Deciphera Pharmaceuticals been receiving favorable news coverage? News coverage about DCPH stock has been trending positive on Monday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Deciphera Pharmaceuticals earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Deciphera Pharmaceuticals. Are investors shorting Deciphera Pharmaceuticals? Deciphera Pharmaceuticals saw a increase in short interest in December. As of December 31st, there was short interest totalling 2,500,000 shares, an increase of 7.8% from the December 15th total of 2,320,000 shares. Based on an average daily trading volume, of 544,200 shares, the days-to-cover ratio is currently 4.6 days. Currently, 8.0% of the shares of the company are sold short. View Deciphera Pharmaceuticals' Current Options Chain. Who are some of Deciphera Pharmaceuticals' key competitors? Some companies that are related to Deciphera Pharmaceuticals include Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Beigene (BGNE), Sarepta Therapeutics (SRPT), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Horizon Therapeutics (HZNP). What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include Ionis Pharmaceuticals (IONS), Allena Pharmaceuticals (ALNA), Exelixis (EXEL), Fate Therapeutics (FATE), Global Blood Therapeutics (GBT), Iovance Biotherapeutics (IOVA), Viking Therapeutics (VKTX), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Crispr Therapeutics (CRSP). Who are Deciphera Pharmaceuticals' key executives? Deciphera Pharmaceuticals' management team includes the folowing people: Dr. Daniel L. Flynn, Exec. VP, Chief Scientific Officer & Founder (Age 64)Mr. Christopher J. Morl, Chief Bus. Officer (Age 60)Countess Steven L. Hoerter, Pres, CEO & Director (Age 48)Mr. Thomas Patrick Kelly J.D., Exec. VP, CFO & Treasurer (Age 48)Dr. Stephen B. Ruddy Ph.D., Chief Technical Officer (Age 55) When did Deciphera Pharmaceuticals IPO? (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers. How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Deciphera Pharmaceuticals' stock price today? One share of DCPH stock can currently be purchased for approximately $69.40. How big of a company is Deciphera Pharmaceuticals? Deciphera Pharmaceuticals has a market capitalization of $3.54 billion. The company earns $-99,850,000.00 in net income (profit) each year or ($2.82) on an earnings per share basis. Deciphera Pharmaceuticals employs 112 workers across the globe.View Additional Information About Deciphera Pharmaceuticals. What is Deciphera Pharmaceuticals' official website? The official website for Deciphera Pharmaceuticals is http://www.deciphera.com/. How can I contact Deciphera Pharmaceuticals? Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected] MarketBeat Community Rating for Deciphera Pharmaceuticals (NASDAQ DCPH)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 247 (Vote Outperform)Underperform Votes: 240 (Vote Underperform)Total Votes: 487MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe DCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DCPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2020 by MarketBeat.com StaffFeatured Article: Why are gap-down stocks important?
